• Detects SNVs, Indels, CNVs, and rearrangements
• Designed to predict responses to immunotherapies and targeted therapies
• Measures critical biomarkers in B-cell malignancies
• Multiple sample types acceptable for testing
*PredicineHEME™ is for RUO.
PredicineHEME™ is a 106 gene assay that targets known mutations associated with B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). The assay can help guide decisions for immunotherapy, targeted therapy and relevant clinical trials for blood cancers. It is currently used in clinical research.
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.
If you have any questions or need assistance, complete this form and we will respond within 24 hours.